Abstract
Despite disappointments with early clinical studies, there is continued interest in the development of gene therapy for the group of metabolic diseases referred to as lysosomal storage disorders (LSDs). The LSDs are monogenic and several small and large, representative animal models of the human diseases are available. Further, the successful reconstitution of only low and unregulated tissue levels of the affected lysosomal enzymes are expected to be sufficient to correct the disease at least in the case of some of the LSDs. For these reasons, they are perceived as good models for the evaluation of different gene delivery vectors and of different strategies for treating chronic genetic diseases by gene transfer. In this review, we will highlight the progress that has been made over the past 2 years in preclinical research for this group of disorders and speculate on future prospects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Suzuki K . Lysosomal diseases. In: Graham DI, Lantos PL (eds) Greenfield's Neuropathology. Arnold: London, 2002, pp 653–735.
Wraith JE . Advances in the treatment of lysosomal storage disease. Dev Med Child Neurol 2001; 43: 639–646.
Weinreb NJ et al. Effectiveness of enzyme replacement therapy in 1028 patients with Type I Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registry. Am J Med 2002; 113: 112–119.
Eng CM et al. Safety and efficacy of recombinant human α-galactosidase A replacement in Fabry disease. N Engl J Med 2001; 345: 9–16.
Schiffman R et al. Enzyme replacement therapy in Fabry disease: a randomised controlled trial. JAMA 2001; 285: 2743–2749.
Neufeld EF, Muenzer J . The mucopolysaccharidoses. In: Scriver CR, Beaudet, AL, Sly WS, Valle D (eds) The Metabolic and Molecular Basis of Inherited Disease. McGraw-Hill: New York, 2001, pp 3421–3452.
Novelli EM, Barranger JA . Gene therapy for lysosomal storage disorders. Expert Opin Biol Ther 2001; 1: 857–867.
Miranda et al. Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann–Pick disease. Gene Therapy 2000; 7: 1768–1776.
Matzner U, Habetha M, Gieselmann V . Retrovirally expressed human arylsulfatase A corrects the metabolic defect of arylsulfatase A-deficient mouse cells. Gene Therapy 2000; 7: 805–812.
Qin G et al. Preselective gene therapy for Fabry disease. Proc Natl Acad Sci USA 2001; 98: 3428–3433.
Leimig et al. Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells. Blood 2002; 99: 3169–3178.
Halene S, Kohn DB . Gene therapy using hematopoietic cells: sisyphus approaches the crest. Hum Gene Ther 2000; 11: 1259–1267.
Horn PA et al. Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells. Blood 2002; 100: 3960–3967.
Vigna E, Naldini L . Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000; 2: 308–316.
Cavazzana-Calvo M et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669–672.
Marshall J et al. Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model. Mol Ther 2002; 6: 179–189.
Du H et al. Lysosomal acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice. Hum Gene Ther 2002; 13: 1361–1372.
Przybylska MJ et al. Correction of the α-galactosidase A deficiency in Fabry mice using synthetic gene delivery vectors. Mol Ther 2002; 5: S343.
Niidome T, Huang L . Gene therapy progress and prospects: nonviral vectors. Gene Therapy 2002; 9: 1647–1652.
Ross CJD et al. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther 2000; 11: 2117–2127.
Atthanaspoulos T, Fabb S, Dickson G . Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases. Int J Mol Med 2000; 6: 363–375.
Zaiss AK et al. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002; 76: 4580–4590.
Mount JD et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002; 99: 2670–2676.
Jung SC et al. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci USA 2001; 98: 2676–2681.
Takahashi H et al. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci USA 2002; 99: 13777–13782.
Fraites TJ et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 2002; 5: 571–578.
Daly TM et al. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Therapy 2001; 8: 1291–1298.
Fu H et al. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol Ther 2002; 5: 42–49.
Gao G et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854–11859.
Gao C, Sands MS, Haskins ME, Ponder KP . Delivery of a retroviral vector expressing human β-glucuronidase to the liver and spleen decreases lysosomal storage in mucopoly-saccharidosis VII mice. Mol Ther 2000; 2: 233–244.
Stein CS et al. In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol Ther 2001; 3: 850–856.
Xu L et al. Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of β-glucuronidase in mucopolysaccharidosis VII dogs. Mol Ther 2002; 5: 141–153.
Ponder KP et al. Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc Natl Acad Sci USA 2002; 99: 13102–13107.
Wang L et al. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 2000; 1: 154–158.
Ziegler R et al. Improved adeno-associated viral vectors for gene therapy of Fabry disease. Mol Ther 2002; 5: S91.
Daly TM et al. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Therapy 2001; 8: 1291–1298.
Ding E et al. Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol Ther 2002; 5: 436–446.
Martin-Touaux E et al. Muscle as a putative producer of acid glucosidase for glycogenosis type II gene therapy. Hum Mol Genet 2002; 11: 1637–1645.
Raben N et al. Conditional tissue-specific expression of the acid α-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum Mol Genet 2001; 10: 2039–2047.
Agu RU et al. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001; 2: 198–209.
Zabner J et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74: 3852–3858.
Kobinger GP, Weiner DJ, Yu QC, Wilson JM . Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 2001; 19: 225–230.
Li C et al. Adenovirus-transduced lung as a portal for delivering α-galactosidase A into systemic circulation for Fabry disease. Mol Ther 2002; 5: 745–754.
Auricchio A et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest 2002; 110: 499–504.
Frisella WA et al. Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis Type VII. Mol Ther 2001; 3: 351–358.
Brooks AI et al. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci USA 2002; 99: 6216–6221.
Consiglio A et al. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat Med 2001; 7: 310–316.
Passini MA, Lee EB, Heuer GG, Wolfe JH . Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J Neurosci 2002; 22: 6437–6446.
Xia H, Mao Q, Davidson BL . The HIV Tat protein transduction domain improves the biodistribution of β-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 2001; 19: 640–644.
Clackson T . Regulated gene expression systems. Gene Therapy 2000; 7: 120–125.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cheng, S., Smith, A. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther 10, 1275–1281 (2003). https://doi.org/10.1038/sj.gt.3302092
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302092
Keywords
This article is cited by
-
Secondary Alterations of Sphingolipid Metabolism in Lysosomal Storage Diseases
Neurochemical Research (2011)
-
Deregulated Sphingolipid Metabolism and Membrane Organization in Neurodegenerative Disorders
Molecular Neurobiology (2010)
-
Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders
Journal of Inherited Metabolic Disease (2010)
-
Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery
Gene Therapy (2009)
-
Effect of elongation factor 1α promoter and SUMF1 over in vitro expression of N-acetylgalactosamine-6-sulfate sulfatase
Molecular Biology Reports (2009)